ELAN vs. PFE: Elanco Animal Health vs. Pfizer Stock Comparison
How do Elanco Animal Health (ELAN) and Pfizer (PFE) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.
Company Profile
Elanco Animal Health (ELAN) and Pfizer (PFE) are both classified in the Pharmaceuticals sub-industry within the broader Pharmaceuticals industry, placing them in the closest GICS peer bucket.
| Profile Item | ELAN | PFE |
|---|---|---|
| Name | Elanco Animal Health Incorporated | Pfizer Inc. |
| Country/Region | United States | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry Group | Pharmaceuticals, Biotechnology & Life Sciences | Pharmaceuticals, Biotechnology & Life Sciences |
| GICS Industry | Pharmaceuticals | Pharmaceuticals |
| GICS Sub-Industry | Pharmaceuticals | Pharmaceuticals |
| Market Capitalization | 12.86 billion USD | 167.52 billion USD |
| Currency | USD | USD |
| Exchange | NYSE | NYSE |
| Listing Date | September 20, 2018 | June 1, 1972 |
| Security Type | Common Stock | Common Stock |
Price Performance
Cumulative Growth
Trailing Returns
Calendar-Year Returns
Performance Metrics
| Metric | ELAN | PFE |
|---|---|---|
| Total Return (1Y) | 24.03% | 28.65% |
| Total Return (3Y, Annualized) | 37.47% | 6.41% |
| Total Return (5Y, Annualized) | -4.24% | -3.98% |
Risk Profile
Drawdown History
Return Distribution
Risk Metrics
Elanco Animal Health (ELAN) has an aggressive beta of 1.65, indicating higher sensitivity to broad-market moves, while Pfizer (PFE) is defensive at 0.35 and tends to be less market-sensitive — they sit on opposite ends of the beta spectrum.
| Metric | ELAN | PFE |
|---|---|---|
| Volatility (1Y, Annualized) | 43.57% | 21.72% |
| Beta (5Y) | 1.65 | 0.35 |
| Max Drawdown (5Y) | -75.59% | -58.96% |
| Avg. Volume (3M) | 5.65M | 33.67M |
Risk-Adjusted Performance
Risk-Return Positioning
Risk-Adjusted Metrics
| Metric | ELAN | PFE |
|---|---|---|
| Sharpe Ratio (1Y) | 0.45 | 1.12 |
| Sortino Ratio (1Y) | 0.66 | 1.73 |
Profitability
ROE (TTM)
Capital efficiency shows on one side only: Pfizer (PFE) earns 4.47% on shareholders’ equity, ranked against its industry; Elanco Animal Health (ELAN) has no ROE this period.
ELAN
Pharmaceuticals, Biotechnology & Life Sciences industry group
--
- Max
- 109.18%
- Q3
- 6.23%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
- ELAN
- --
PFE
Pharmaceuticals, Biotechnology & Life Sciences industry group
4.47%
- Max
- 109.18%
- Q3
- 6.23%
- PFE
- 4.47%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
Net Margin (TTM)
Elanco Animal Health (ELAN) reports a negative net margin of -2.86%, usually indicating a net loss over the period. Meanwhile Pfizer (PFE) reports 6.34%, ranking against industry peers normally.
ELAN
Pharmaceuticals, Biotechnology & Life Sciences industry group
-2.86%
- Max
- 18.05%
- Q3
- 4.78%
- Median
- 0.00%
- ELAN
- -2.86%
- Q1
- -4.14%
- Min
- -17.05%
PFE
Pharmaceuticals, Biotechnology & Life Sciences industry group
6.34%
- Max
- 18.05%
- PFE
- 6.34%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
Operating Margin (TTM)
Pfizer (PFE) at 33.38% operates in the top operating margin quartile, ahead of Elanco Animal Health (ELAN) at 6.64%, which runs around its industry’s norm.
ELAN
Pharmaceuticals, Biotechnology & Life Sciences industry group
6.64%
- Max
- 83.12%
- Q3
- 14.77%
- ELAN
- 6.64%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
PFE
Pharmaceuticals, Biotechnology & Life Sciences industry group
33.38%
- Max
- 83.12%
- PFE
- 33.38%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
Profitability Metrics
| Metric | ELAN | PFE |
|---|---|---|
| ROE (TTM) | -- | 4.47% |
| ROA (TTM) | -- | 5.59% |
| Net Margin (TTM) | -2.86% | 6.34% |
| Operating Margin (TTM) | 6.64% | 33.38% |
| Gross Margin (TTM) | 56.18% | 74.90% |
Growth
Revenue Growth
Elanco Animal Health (ELAN) at 6.22% is around its peer norm for revenue growth, while Pfizer (PFE) at -1.65% drops into the bottom quartile, signaling weaker demand or pricing momentum.
EPS Growth
Pfizer (PFE) at -3.55% is around its peer norm for EPS growth, while Elanco Animal Health (ELAN) at -169.12% drops into the bottom quartile, signaling weaker earnings momentum.
Growth Metrics
| Metric | ELAN | PFE |
|---|---|---|
| Revenue Growth (YoY) | 6.22% | -1.65% |
| Revenue Growth (3Y CAGR) | 2.25% | -14.80% |
| EPS Growth (YoY) | -169.12% | -3.55% |
| EPS Growth (3Y CAGR) | -- | -37.12% |
Financial Strength
Current Ratio (MRQ)
Short-term liquidity can only be read on one side of this pairing: Pfizer (PFE) shows current ratio of 1.42 against its industry benchmark, while Elanco Animal Health (ELAN) has no reading this period.
ELAN
Pharmaceuticals, Biotechnology & Life Sciences industry group
--
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- Q1
- 2.47
- Min
- 0.10
- ELAN
- --
PFE
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.42
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- Q1
- 2.47
- PFE
- 1.42
- Min
- 0.10
Debt / Equity (MRQ)
Elanco Animal Health (ELAN) at 0.64 carries an industry-typical debt-to-equity mix, while Pfizer (PFE) at 0.71 uses more debt funding than most peers.
ELAN
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.64
- Max
- 1.42
- Q3
- 0.65
- ELAN
- 0.64
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
PFE
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.71
- Max
- 1.42
- PFE
- 0.71
- Q3
- 0.65
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
Financial Strength Metrics
| Metric | ELAN | PFE |
|---|---|---|
| Current Ratio (MRQ) | -- | 1.42 |
| Debt / Equity (MRQ) | 0.64 | 0.71 |
| Net Debt / EBITDA | 3.49 | 1.97 |
Dividends
Dividend Yield (TTM)
Elanco Animal Health (ELAN) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Pfizer (PFE) reports a yield of 7.30%, ranking against industry peers normally.
ELAN
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- ELAN
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
PFE
Pharmaceuticals, Biotechnology & Life Sciences industry group
7.30%
- PFE
- 7.30%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Payout Ratio (TTM)
Pfizer (PFE) reports payout ratio above 100% at 245.71%, meaning dividends exceeded current-period earnings; Elanco Animal Health (ELAN) pays no dividend (payout 0.00%).
ELAN
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- ELAN
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
PFE
Pharmaceuticals, Biotechnology & Life Sciences industry group
245.71%
- PFE
- 245.71%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Metrics
| Metric | ELAN | PFE |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 7.30% |
| Dividend Payout Ratio (TTM) | 0.00% | 245.71% |
Valuation
P/E Ratio (TTM)
An earnings multiple is available for just one side: Pfizer (PFE) trades at 41.99 times trailing earnings, ranked against its peers, while Elanco Animal Health (ELAN) has no P/E ratio this period.
ELAN
Pharmaceuticals, Biotechnology & Life Sciences industry group
--
- Max
- 85.34
- Q3
- 43.46
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
- ELAN
- --
PFE
Pharmaceuticals, Biotechnology & Life Sciences industry group
41.99
- Max
- 85.34
- Q3
- 43.46
- PFE
- 41.99
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
P/S Ratio (TTM)
Both Elanco Animal Health (ELAN) at 2.50 and Pfizer (PFE) at 2.63 fetch a relatively low price per dollar of sales, landing in the cheaper P/S ratio quartile of their industries.
ELAN
Pharmaceuticals, Biotechnology & Life Sciences industry group
2.50
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- Q1
- 3.01
- ELAN
- 2.50
- Min
- 0.01
PFE
Pharmaceuticals, Biotechnology & Life Sciences industry group
2.63
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- Q1
- 3.01
- PFE
- 2.63
- Min
- 0.01
P/B Ratio (MRQ)
On P/B ratio, both Elanco Animal Health (ELAN) at 1.95 and Pfizer (PFE) at 1.88 are valued close to their industries’ norm against book — neither stands out from peers.
ELAN
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.95
- Max
- 13.53
- Q3
- 6.54
- Median
- 3.25
- ELAN
- 1.95
- Q1
- 1.69
- Min
- -5.59
PFE
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.88
- Max
- 13.53
- Q3
- 6.54
- Median
- 3.25
- PFE
- 1.88
- Q1
- 1.69
- Min
- -5.59
Valuation Metrics
| Metric | ELAN | PFE |
|---|---|---|
| P/E Ratio (TTM) | -- | 41.99 |
| P/S Ratio (TTM) | 2.50 | 2.63 |
| P/B Ratio (MRQ) | 1.95 | 1.88 |
| Free Cash Flow Yield (TTM) | -- | 7.76% |